OpGen (NASDAQ:OPGN) Earns Sell Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of OpGen (NASDAQ:OPGN) in a research report sent to investors on Saturday. The brokerage issued a sell rating on the medical research company’s stock.

OpGen Trading Up 23.3 %

Shares of OPGN opened at $0.93 on Friday. The firm has a 50-day simple moving average of $1.31 and a two-hundred day simple moving average of $1.93. OpGen has a 1-year low of $0.53 and a 1-year high of $9.90.

About OpGen

OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.